CALCIMORE

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

CALCIUM CARBONATE

متاح من:

TARO PHARMACEUTICAL INDUSTRIES LTD

ATC رمز:

A12AA04

الشكل الصيدلاني:

CHEWABLE TABLETS

تركيب:

CALCIUM CARBONATE 600 MG

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Not required

المصنعة من قبل:

TARO PHARMACEUTICAL INDUSTRIES LTD

المجموعة العلاجية:

CALCIUM CARBONATE

المجال العلاجي:

CALCIUM CARBONATE

الخصائص العلاجية:

Antacid, calcium deficiency.

تاريخ الترخيص:

2021-04-30

نشرة المعلومات

PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS
(PREPARATIONS) - 1986
This medicine is dispensed without a doctor's prescription
C
ALCIMORE
CHEWABLE TABLETS
600 MG
ACTIVE INGREDIENT
Each tablet contains 600 mg calcium carbonate
Inactive ingredients and allergens: see section 2 under ‘Important
information about some of
this medicine’s ingredients’, and section 6 ‘Additional
information'.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE. This leaflet
contains concise information about this medicine. If you have any
further questions, consult
your doctor or pharmacist.
Take this medicine according to the instructions in the section about
dose in this leaflet.
Consult your pharmacist if you need further information. If you are
taking Calcimore to treat
excess acid and heartburn, consult your doctor if your symptoms of
illness get worse or do
not improve within 14 days.
1. WHAT IS THIS MEDICINE INTENDED FOR?
This medicine is used as an antacid. It is also used to treat calcium
deficiency.
THERAPEUTIC GROUP: mineral supplement; antacid.
Calcimore - chewable tablets contain calcium, which is important in
bone formation. Calcium
is found in the diet. Calcium deficiency can happen when your diet or
lifestyle does not
provide the amount of calcium you need, or when body requirements are
increased.
2. BEFORE USING THIS MEDICINE:
DO NOT USE THIS MEDICINE IF:
SPECIAL WARNINGS ABOUT USING THIS MEDICINE
TALK TO YOUR DOCTOR BEFORE TAKING CALCIMORE IF:
•
YOU HAVE OSTEOPOROSIS (BRITTLE BONES) and are also unable to move
around
•
you are on long term treatment, especially if you are taking medicines
for a HEART
DISORDER (glycosides), or DIURETICS (used in the treatment of high
blood pressure or
oedema)
•
you have signs of IMPAIRED KIDNEY FUNCTION or a high tendency to
kidney stone
formation
•
if you have CANCER or other conditions that may have affected your
bones
•
you are sensitive (allergic) to calcium or to any of the other
ingredients in this
medicine (see section 6)
•

خصائص المنتج

Calcimore Physician Leaflet Proposal 05.2021
SUMMARY OF PRODUCT CHARACTERISTIC
1.
NAME OF THE MEDICINAL PRODUCT
Calcimore
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains 600 mg of calcium carbonate.
Excipients with known effect: sodium, sucrose.
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable Tablets.
White biconvex tablets. One side engraved with 'Taro'. Other side
plain.
Peppermint Odor.
4.
CLINICAL PARTICULARS
4.1. THERAPEUTIC INDICATIONS
Antacid, calcium deficiency.
4.2. POSOLOGY AND METHOD OF ADMINISTRATION:
POSOLOGY
Antacid: 1-2 tablets as needed
Calcium deficiency: 2 tablets 1-3 times a day, 1-1.5 hours after
meals.
Do not exceed the recommended dosage.
This medicine is not usually intended for administration to children
under 6
years of age, unless recommended by a doctor.
For increased stomach acidity: If there is no improvement in your
condition
within 14 days, refer to your doctor.
METHOD OF ADMINISTRATION
Oral.
Tablets should be chewed.
4.3. CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1.

Diseases and/or conditions resulting in hypercalcaemia and/or
hypercalciuria, for example in hyperparathyroidism, vitamin D
overdosage, decalcifying tumours such as plasmacytoma and
skeletal metastases, in severe renal failure untreated by renal
dialysis
and in osteoporosis due to immobilisation.

Renal calculi (nephrolithiasis)

Patients on a low phosphate diet.

Patients with Zollinger-Ellison Syndrome.

Patients on cardiac glycosides
Calcimore Physician Leaflet Proposal 05.2021
4.4. SPECIAL WARNINGS AND PRECAUTIONS FOR USE
In renal insufficiency the tablets should be given only under
controlled
conditions for hyperphosphataemia. Caution should be exercised in
patients
with a history of renal calculi.
Monitoring is especially important in patients on concomitant
treatment with
or diuretics (see section 4.5).
During high dose therapy and especially during concomitant treatment
wi